Nurix Therapeutics, Inc. (Nasdaq: NRIX) is making waves in the biopharmaceutical landscape with its innovative approach to drug design. Focused on the discovery, development, and commercialization of targeted protein degradation medicines, the company aims to enhance treatment options for patients battling cancer and inflammatory diseases. Headquartered in San Francisco, California, Nurix has positioned itself at the forefront of this cutting-edge field with a robust clinical pipeline and strategic partnerships.

2. Inducement Grants Announcement

On February 14, 2025, Nurix Therapeutics announced the granting of inducement awards to nine new employees as part of its 2024 Equity Inducement Plan. This initiative is designed to incentivize talented individuals to join the company, aligning with Nasdaq Listing Rule 5635(c)(4). The awards were approved by the Compensation Committee of Nurix’s Board of Directors and are intended to support the company’s growth and innovation strategy.

Details of the Grants

The inducement awards consist of stock options and restricted stock unit awards (RSUs). Specifically, Nurix granted:

Stock Options: An aggregate of 208,350 shares of common stock, with an exercise price set at $17.12 per share, equivalent to the closing price on the grant date. These options have a ten-year term, and vesting will occur as follows:

One-fourth will vest on the one-year anniversary of the employee's hire date.

The remaining shares will vest at a rate of one forty-eighth each month until fully vested by the fourth anniversary of the hire date, contingent upon the employee's continued service.

Restricted Stock Units (RSUs): An aggregate of 272,850 shares, with vesting stipulations based on employment start dates:

For employees who commenced service prior to January 31, 2025, one-fourth of the shares will vest on the one-year anniversary of the vesting start date (January 30, 2025).

For those starting on or after January 31, 2025, the initial vesting will occur on April 30, 2025.

Subsequent vesting will occur quarterly at a rate of one sixteenth until fully vested by the fourth anniversary of the vesting start date, also subject to continued service.

3. Strategic Implications

The granting of these inducement awards reflects Nurix's commitment to attracting high-caliber talent as it advances its pipeline of targeted therapies. With a focus on innovative drug design, the company is poised to leverage the expertise of its new hires to further its mission of developing next-generation treatments for challenging medical conditions.

Nurix’s clinical pipeline includes multiple promising candidates, such as degraders of Bruton’s tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). These assets are crucial in addressing unmet medical needs in oncology and immunology. Additionally, Nurix's collaborations with prominent pharmaceutical companies, including Gilead Sciences, Sanofi, and Pfizer, underscore its potential for impactful advancements in drug discovery.

4. Looking Ahead

As Nurix Therapeutics continues to grow and innovate, the inducement grants serve as a strategic tool to build a strong team dedicated to the company's vision. By investing in talent, Nurix is not only enhancing its operational capabilities but also reinforcing its position as a leader in the biopharmaceutical sector. The company's unique approach to targeted protein degradation could very well write the next chapter in the treatment of complex diseases, setting new standards in patient care.

For more information about Nurix Therapeutics, interested parties can visit their website at www.nurixtx.com.

5. Contact Information

For further inquiries, the company has provided the following contacts:

Investors

Jason Kantor, Ph.D.

ir@nurixtx.com

Elizabeth Wolffe, Ph.D.

Wheelhouse Life Science Advisors

lwolffe@wheelhouselsa.com

Media

Aljanae Reynolds

Wheelhouse Life Science Advisors

areynolds@wheelhouselsa.com

Original press release